您现在的位置是:首页>权威专家> 肾癌

Philip Philip M.D., Ph.D., F.R.C.P

Philip Philip M.D., Ph.D., F.R.C.P

所在科室:外科

就职医院:Karmanos cancer center

医生擅长:

在线咨询医学顾问 电话热线:400-666-7998

医生介绍

 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Gastrointestinal Oncology 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Adrenal Cancer 
Anal Cancer 
Ampullary and periampullary cancers 
Appendix Cancer 
Bile Duct Cancer 
Cancer of unknown origin 
Carcinoid Tumors 
Cholangiocarcinoma 
colon Cancer 
Esophageal Cancer 
Gall Bladder Cancer 
Gastroesophageal Junction (GEJ) 
Gastrointestinal Stromal Tumors (GIST) 
Liver Cancer 
Neuroendocrine Tumors 
Pancreatic Cancer 
Pancreatic Neuroendocrine Tumor (pNET) 
Peritoneum and psuedomyxoma peritonii 
Rectal Cancer 
Small Intestine Cancer 
Stomach Cancer 

·         Contact Info

·         Email:
philipp@karmanos.org

 

来自 <http://www.karmanos.org/physicians/Philip-Philip?Disease=229&PageIndex=0&SortDirection=1>

 

·         Education

·         Fellowship
Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology and the Lymphoma Unit, Guy's Hospital Medical School, University of London, London, United Kingdom
Fellowship
Medical Oncology, MD Anderson Cancer Center, Houston, Texas
Medical School
University of Baghdad, College of Medicine
Residency
Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq
Residency
Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of Baghdad, Baghdad, Iraq
Graduate Training
Clinical Pharmacology & Pharmacogenetics, University of London

·         Professional Memberships/Associations

·         European Organization for Research and Treatment of Cancer (Pharmacology and Molecular Mechanisms Group) 
American Association for Cancer Research 
American Society of Clinical Oncology 
American Society of Clinical Pharmacology and Therapeutics 
Southwest oncology Group (Leader – Pancreas Cancer Subcommittee and member of the Steering Committee for GI Cancer) 
American Pancreatic Association 

·         Board Certifications

·         American Board of Internal Medicine
Medical Oncology

·         Clinical Interests

·         Medical Oncologist 

·         Research Interests

·         Novel therapies for GI cancers (liver, pancreas, biliary, colon, rectum, carcinoid, GIIST, stomach, esophagus, anal) 

·         Profile

·         Philip is a Professor of Medicine at Wayne State University School of Medicine and a Clinical Professor of oncology at the Barbara Ann Karmanos Cancer Institute in Detroit, MI. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. Philip Philip’s primary research focus is the oversight of clinical trials of novel therapeutic agents and therapeutic combinations on patients with pancreatic, gastro-esophageal, liver, and colorectal cancer. He is actively involved in Phase I and II clinical trials. Philip has received numerous awards, including the Wayne State University Medical School Teaching Award (1999, 2004), and Outstanding Instructor in oncology Award (2001). He belongs to numerous professional organizations including the American pancreatic Association and the American Society of Clinical Oncology. Philip serves on the Editorial Board of the Internet Journal of oncology and Community oncology and reviews for multiple journals, including the Journal of Clinical oncology and the European Journal of Cancer. He has authored over 70 articles in peer-reviewed journal, 7 book chapters and many invited review articles. Philip received his BA (1971, American Jesuit Fathers College, Baghdad, Iraq), MD (1977, University of Baghdad College of Medicine), and PhD in Clinical Pharmacology and Pharmacogenetics (1986, University of London, UK). He trained in oncology at the University of Oxfor(UK) and the MD Anderson Cancer Center.

·         Awards

·         Best Doctors of America
Wayne State University School of Medicine Teaching
2001 Outstanding Instructor in oncology Award, WSU
Voted one of Best Doctors Inc. 2011-2014 Best Doctors of the Year

·         Publications

·         Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2011 May;2(5):378-92. PMID: 21623005; PMCID: PMC3248191. Authors: Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM.
Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res. 2011 Aug 15;3(4):374-82. Epub 2011 Jul 26. PubMed PMID: 21904657; PubMed Central PMCID: PMC3158739. Authors: Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH.
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2011 Sep 27. doi: 10.1002/cncr.26556. [Epub ahead of print] PMID: 21953248. Authors: Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C.
Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol. 2011 Dec 29. doi: 10.1002/jcp.24036. [Epub ahead of print] PMID: 22213426. Authors: Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, Sarkar FH.
Locally advanced pancreatic cancer: wher should we go from here? J Clin Oncol. 2011 Nov 1;29(31):4066-8. Epub 2011 Oct 3. PMID: 21969514. Author: Philip PA.

 

相关报道资讯

视频科普

胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医
胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医

简介: 胃癌IV期伴有肝脏及肝胃间隙淋巴结转移,国内无标准方案,会诊得知这里胃癌5年生存率相比要高。习惯了家里的医院,还真不适应... 更多»

大肠癌伴肝转移患者赴日就医
大肠癌伴肝转移患者赴日就医

简介:大肠癌伴肝转移,本想国内治疗,但通过日ben癌研有明医院在线会诊,家人支持来院手术。非常顺利4小时完成切除和淋巴结清扫,第二... 更多»

胶质母细胞瘤和髓母细胞瘤患者赴日就医
胶质母细胞瘤和髓母细胞瘤患者赴日就医

简介: 你经历过绝望到希望吗?在国内先后被诊断为胶质母细胞瘤和髓母细胞瘤的患者。术后只做了脑部放疗,复发了。最后参加了日ben国... 更多»

肝癌患者日本国际就医案例
肝癌患者日本国际就医案例

简介: 肝癌,多年前在日ben癌研有明病院做的手术,这次来复查,结果很满意,但是还需3个月后再次复查,6月份再来,明日回国,感谢帮... 更多»

癌症患者的新方案来了!数十位国际专家带先进技术助力国内癌症患者
癌症患者的新方案来了!数十位国际专家带先进技术助力国内癌症患者

简介:癌症患者的新方案来了!数十位国际专家带先进技术助力国内癌症患者... 更多»

在线预约

绿色快速预约通道

Philip Philip M.D., Ph.D., F.R.C.P

请正确填写预约人和联系人等信息,提交需求成功后,请保持联系电话畅通,客服会在48小时内与您联系确认信息。客服热线:400-666-7998

Philip Philip M.D., Ph.D., F.R.C.P

Karmanos cancer center 外科

擅长

简介

 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Gastrointestinal Oncology 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Adrenal Cancer 
Anal Cancer 
Ampullary and periampullary cancers 
Appendix Cancer 
Bile Duct Cancer 
Cancer of unknown origin 
Carcinoid Tumors 
Cholangiocarcinoma 
colon Cancer 
Esophageal Cancer 
Gall Bladder Cancer 
Gastroesophageal Junction (GEJ) 
Gastrointestinal Stromal Tumors (GIST) 
Liver Cancer 
Neuroendocrine Tumors 
Pancreatic Cancer 
Pancreatic Neuroendocrine Tumor (pNET) 
Peritoneum and psuedomyxoma peritonii 
Rectal Cancer 
Small Intestine Cancer 
Stomach Cancer 

·         Contact Info

·         Email:
philipp@karmanos.org

 

来自 <http://www.karmanos.org/physicians/Philip-Philip?Disease=229&PageIndex=0&SortDirection=1>

 

·         Education

·         Fellowship
Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology and the Lymphoma Unit, Guy's Hospital Medical School, University of London, London, United Kingdom
Fellowship
Medical Oncology, MD Anderson Cancer Center, Houston, Texas
Medical School
University of Baghdad, College of Medicine
Residency
Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq
Residency
Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of Baghdad, Baghdad, Iraq
Graduate Training
Clinical Pharmacology & Pharmacogenetics, University of London

·         Professional Memberships/Associations

·         European Organization for Research and Treatment of Cancer (Pharmacology and Molecular Mechanisms Group) 
American Association for Cancer Research 
American Society of Clinical Oncology 
American Society of Clinical Pharmacology and Therapeutics 
Southwest oncology Group (Leader – Pancreas Cancer Subcommittee and member of the Steering Committee for GI Cancer) 
American Pancreatic Association 

·         Board Certifications

·         American Board of Internal Medicine
Medical Oncology

·         Clinical Interests

·         Medical Oncologist 

·         Research Interests

·         Novel therapies for GI cancers (liver, pancreas, biliary, colon, rectum, carcinoid, GIIST, stomach, esophagus, anal) 

·         Profile

·         Philip is a Professor of Medicine at Wayne State University School of Medicine and a Clinical Professor of oncology at the Barbara Ann Karmanos Cancer Institute in Detroit, MI. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. Philip Philip’s primary research focus is the oversight of clinical trials of novel therapeutic agents and therapeutic combinations on patients with pancreatic, gastro-esophageal, liver, and colorectal cancer. He is actively involved in Phase I and II clinical trials. Philip has received numerous awards, including the Wayne State University Medical School Teaching Award (1999, 2004), and Outstanding Instructor in oncology Award (2001). He belongs to numerous professional organizations including the American pancreatic Association and the American Society of Clinical Oncology. Philip serves on the Editorial Board of the Internet Journal of oncology and Community oncology and reviews for multiple journals, including the Journal of Clinical oncology and the European Journal of Cancer. He has authored over 70 articles in peer-reviewed journal, 7 book chapters and many invited review articles. Philip received his BA (1971, American Jesuit Fathers College, Baghdad, Iraq), MD (1977, University of Baghdad College of Medicine), and PhD in Clinical Pharmacology and Pharmacogenetics (1986, University of London, UK). He trained in oncology at the University of Oxfor(UK) and the MD Anderson Cancer Center.

·         Awards

·         Best Doctors of America
Wayne State University School of Medicine Teaching
2001 Outstanding Instructor in oncology Award, WSU
Voted one of Best Doctors Inc. 2011-2014 Best Doctors of the Year

·         Publications

·         Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2011 May;2(5):378-92. PMID: 21623005; PMCID: PMC3248191. Authors: Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM.
Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res. 2011 Aug 15;3(4):374-82. Epub 2011 Jul 26. PubMed PMID: 21904657; PubMed Central PMCID: PMC3158739. Authors: Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH.
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2011 Sep 27. doi: 10.1002/cncr.26556. [Epub ahead of print] PMID: 21953248. Authors: Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C.
Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol. 2011 Dec 29. doi: 10.1002/jcp.24036. [Epub ahead of print] PMID: 22213426. Authors: Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, Sarkar FH.
Locally advanced pancreatic cancer: wher should we go from here? J Clin Oncol. 2011 Nov 1;29(31):4066-8. Epub 2011 Oct 3. PMID: 21969514. Author: Philip PA.

 

TA的文章视频